World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 30 June 2019
Main ID:  EUCTR2012-002699-14-GB
Date of registration: 03/07/2012
Prospective Registration: Yes
Primary sponsor: Pharmaxis Ltd.
Public title: Trial of inhaled mannitol in children with cystic fibrosis
Scientific title: A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years - DPM-CF-204 mannitol in CF aged 6-17 years
Date of first enrolment: 28/01/2013
Target sample size: 160
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002699-14
Study type:  Interventional clinical trial of medicinal product
Study design: 
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: yes
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Belgium Canada France Italy Netherlands United Kingdom
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation:  N/A
Name:    
Address: 
Telephone:
Email:
Affiliation:  N/A
Key inclusion & exclusion criteria
Inclusion criteria:
1. Personally provide, or have a legal guardian provide written informed consent to participate in the trial, according to local regulations;
2. rhDNase and maintenance antibiotic use is allowed but treatment must have been established at least 3months prior to screening. The subject must remain on rhDNase and / or maintenance antibiotics for the duration of the trial. The subject must not commence treatment with rhDNase or maintenance antibiotics during the trial;
3. Have a confirmed diagnosis of cystic fibrosis (sweat test result >= 60 mEq/L chloride and/or genotyping showing two identifiable mutations consistent with a diagnosis of cystic fibrosis);
4. Be aged >= 6 years and < 18 years;
5. Have a percentage of predicted FEV1 of >= 30% and < 90% at Screening (Visit 0). Percentage of predicted FEV1 will be calculated using Wang for children aged < 8 years, and using NHanes III for those >= 8 years; and
6. Be able to perform all the techniques necessary to measure lung function.

Are the trial subjects under 18? yes
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion criteria:
1. Be using maintenance nebulised hypertonic saline Be considered “terminally ill”; eligible for lung transplantation, or have received a lung transplant previously;
2. Require home oxygen or assisted ventilation;
3. Have had an episode of massive haemoptysis defined as acute bleeding =240 ml in a 24-hour period and/or recurrent bleeding =100 ml/day over several days in the three-months prior to Screening (Visit 0);

4. Have a known intolerance to mannitol;
5. Be taking non-selective beta blockers;
6. In the three months prior to Screening (Visit 0) have had a myocardial infarction; a cerebral vascular accident; major ocular, abdominal, chest or brain surgery;
7. Have a known cerebral, aortic or abdominal aneurysm;
8. Be currently participating in, or have participated in another investigative drug trial within four weeks of Screening (Visit 0);
9. Be pregnant or breastfeeding, or plan to become pregnant whilst in the trial;
10. For females of childbearing potential (at the discretion of the investigator), be using an unreliable form of contraception;
11. Have a “failed” or “incomplete” mannitol tolerance test; or
12. Have any concomitant medical, psychiatric, or social condition that, in the Investigator’s opinion, would put the subject at significant risk, may confound the results or may significantly interfere with the subject’s participation in the trial.



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Cystic fibrosis in children aged 6 to 17 years
MedDRA version: 14.1 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disorders
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Intervention(s)

Trade Name: Bronchitol
Product Name: Bronchitol
Product Code: N/A
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: mannitol
CAS Number: 69-95-8
Current Sponsor code: N/A
Other descriptive name: N/A
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use

Primary Outcome(s)
Primary end point(s): The absolute change from each baseline to week 8 of each treatment period in percentage of predicted FEV1.

Secondary Objective: • To determine the effect of inhaled mannitol on FVC;
• To determine the effect of inhaled mannitol on FEF25-75 (exploratory objective) and
• To assess the safety of inhaled mannitol.
• To evaluate the difference in treatment induced sputum weight in patients treated with inhaled mannitol compared to those treated with placebo
Main Objective: To determine the effect of eight weeks of twice-daily treatment with inhaled dry powder mannitol on lung function (FEV1) in subjects with CF who are aged six to seventeen years
Timepoint(s) of evaluation of this end point: Endpoint will be evaluated at the end of the trial.
Secondary Outcome(s)

Secondary end point(s): • Change in percentage of predicted FVC between placebo and mannitol treatment
• Change in percentage of predicted FEF25-75 between placebo and mannitol treatment (exploratory endpoint)
• Adverse events, vital signs and physical examination
• Treatment induced sputum weight
Timepoint(s) of evaluation of this end point: Endpoints will be evaluated at the end of the trial.
Secondary ID(s)
DPM-CF-204
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history